Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins

SARS-CoV-2 variants have evolved over time in recent years, demonstrating immune evasion of vaccine-induced neutralizing antibodies directed against the original S protein. Updated S-targeted vaccines provide a high level of protection against circulating variants of SARS-CoV-2, but this protection...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Evgeniia N. Bykonia, Denis A. Kleymenov, Vladimir A. Gushchin, Andrei E. Siniavin, Elena P. Mazunina, Sofia R. Kozlova, Anastasia N. Zolotar, Evgeny V. Usachev, Nadezhda A. Kuznetsova, Elena V. Shidlovskaya, Andrei A. Pochtovyi, Daria D. Kustova, Igor A. Ivanov, Sergey E. Dmitriev, Roman A. Ivanov, Denis Y. Logunov, Alexander L. Gintsburg
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2024-04-01
Sarja:	Vaccines
Aiheet:	SARS-CoV-2 mRNA vaccine lipid nanoparticles immunogenicity efficacy
Linkit:	https://www.mdpi.com/2076-393X/12/4/379
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!